The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
暂无分享,去创建一个
M. Brechbiel | J. Schlom | R. Madan | J. Gulley | R. Newton | K. Tsang | C. Jochems | R. Donahue | Young-Seung Kim | C. Heery | M. Fantini | J. Hodge | Lauren M. Lepone | I. Grenga | A. Kwilas | R. Fernando | Anna R. Kwilas
[1] Christopher R. Heery,et al. Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types , 2016, Journal of circulating biomarkers.
[2] F. Giles,et al. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy , 2015, Clinical Cancer Research.
[3] Hiroyasu Ito,et al. Induction of hepatitis B virus surface antigen‐specific cytotoxic T lymphocytes can be up‐regulated by the inhibition of indoleamine 2, 3‐dioxygenase activity , 2014, Immunology.
[4] M. Geffard,et al. Aryl hydrocarbon receptor control of a disease tolerance defence pathway , 2014, Nature.
[5] G. Gibney,et al. Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. , 2014 .
[6] H. Koblish,et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment , 2014, Journal of Immunotherapy for Cancer.
[7] J. Schlom,et al. Identification and characterization of agonist epitopes of the MUC1-C oncoprotein , 2014, Cancer Immunology, Immunotherapy.
[8] J. Wolchok,et al. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 , 2013, The Journal of experimental medicine.
[9] P. O'dwyer,et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. , 2013 .
[10] W. J. Ramsey,et al. A phase I study of indoximod in combination with docetaxel in metastatic solid tumors. , 2013 .
[11] P. O'dwyer,et al. Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), in advanced cancer patients. , 2012 .
[12] S. Steinberg,et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.
[13] Kwang Dong Kim,et al. L-kynurenine-induced apoptosis in human NK cells is mediated by reactive oxygen species. , 2011, International immunopharmacology.
[14] D. Munn. Indoleamine 2,3-dioxygenase, Tregs and cancer. , 2011, Current medicinal chemistry.
[15] I. Svane,et al. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. , 2011, Blood.
[16] J. Fechner,et al. An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells , 2010, The Journal of Immunology.
[17] Qian Wang,et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. , 2010, Blood.
[18] F. Essmann,et al. Induction of indoleamine 2, 3-dioxygenase by death receptor activation contributes to apoptosis of melanoma cells via mitochondrial damage-dependent ROS accumulation. , 2010, Cellular signalling.
[19] J. Fridman,et al. Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors , 2010, Molecular Cancer Therapeutics.
[20] K. Isobe,et al. Hemoglobin induces the expression of indoleamine 2,3‐dioxygenase in dendritic cells through the activation of PI3K, PKC, and NF‐κB and the generation of reactive oxygen species , 2009, Journal of cellular biochemistry.
[21] J. Becker,et al. The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase , 2009, PloS one.
[22] B. Baban,et al. IDO Activates Regulatory T Cells and Blocks Their Conversion into Th17-Like T Cells1 , 2009, The Journal of Immunology.
[23] D. Munn,et al. Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. , 2009, Blood.
[24] D. Munn,et al. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. , 2009, Blood.
[25] S. Antonia,et al. Overcoming tumor antigen anergy in human malignancies using the novel indeolamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] D. Munn,et al. The Indoleamine 2,3-Dioxygenase Pathway Is Essential for Human Plasmacytoid Dendritic Cell-Induced Adaptive T Regulatory Cell Generation1 , 2008, The Journal of Immunology.
[27] Minshan Chen,et al. Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma , 2008, Journal of Cancer Research and Clinical Oncology.
[28] H. Kajiyama,et al. Inverse Correlation between Tumoral Indoleamine 2,3-Dioxygenase Expression and Tumor-Infiltrating Lymphocytes in Endometrial Cancer: Its Association with Disease Progression and Survival , 2008, Clinical Cancer Research.
[29] Angela Panoskaltsis-Mortari,et al. Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. , 2008, Blood.
[30] Penny A. Johnson,et al. Mechanisms of local immunosuppression in cutaneous melanoma , 2007, British Journal of Cancer.
[31] T. Shima,et al. Expression of indoleamine 2, 3‐dioxygenase and the recruitment of Foxp3‐expressing regulatory T cells in the development and progression of uterine cervical cancer , 2007, Cancer science.
[32] M. Baccarani,et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. , 2007, Blood.
[33] Stefan Schneeberger,et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] L. Mastracci,et al. Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer. , 2005, Neoplasia.
[35] B. Baban,et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. , 2004, The Journal of clinical investigation.
[36] U. Mellqvist,et al. Oxygen radical‐induced natural killer cell dysfunction: role of myeloperoxidase and regulation by serotonin , 2004, Journal of leukocyte biology.
[37] C. Uyttenhove,et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.
[38] K. Hellstrand. Melanoma immunotherapy: a battle against radicals? , 2003, Trends in immunology.
[39] Ruslan Medzhitov,et al. Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells , 2003, Science.
[40] D. Keskin,et al. Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase , 2002, Science.
[41] Milton W. Taylor,et al. Indoleamine 2,3-Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell Proliferation , 2000, The Journal of Immunology.
[42] D. Munn,et al. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? , 1999, Immunology today.
[43] D. Munn,et al. Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism , 1999, The Journal of experimental medicine.
[44] J. Schlom,et al. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[45] K. Hellstrand,et al. Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. , 1996, Journal of immunology.
[46] J. Schlom,et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. , 1995, Journal of the National Cancer Institute.
[47] M. Sono,et al. 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. , 1991, Archives of biochemistry and biophysics.